10026 Federal Register / Vol. 66, No. 30 / Tuesday, February 13, 2001 / Notices

by PHS intellectual property policies

(see CRADA: http://ott.od.nih.gov/

newpages/crada.pdf).

Licensing Information

This technology was previously

advertised in the December 26, 2000

issue of the Federal Register as a

licensing opportunity [65 FR 81532].

Briefly, the gene and its polymorphisms

that result in the Dombrock blood group

antigenicity, for the first time, provide a

route for reliable blood typing. Products

aimed at improving blood typing

practices through molecular means,

thereby preventing mismatched blood

transfusions, can also be developed with

this technology. For the sake of

completeness, the licensing contact is

provided here: John Rambosek; 301/

496–7056, ext. 270; fax: 301/402–0220;

e-mail: rambosej@od.nih.gov.

Dated: February 5, 2001.

Jack Spiegel,

Director, Division of Technology Development

and Transfer, Office of Technology Transfer.

[FR Doc. 01–3603 Filed 2–12–01; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions;

Availability for Licensing

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The inventions listed below

are owned by agencies of the U.S.

Government and are available for

licensing in the U.S. in accordance with

35 U.S.C. 207 to achieve expeditious

commercialization of results of

federally-funded research and

development. Foreign patent

applications are filed on selected

inventions to extend market coverage

for companies and may also be available

for licensing.

ADDRESSES: Licensing information and

copies of the U.S. patent applications

listed below may be obtained by writing

to the indicated licensing contact at the

Office of Technology Transfer, National

Institutes of Health, 6011 Executive

Boulevard, Suite 325, Rockville,

Maryland 20852–3804; telephone: 301/

496–7057; fax: 301/402–0220. A signed

Confidential Disclosure Agreement will

be required to receive copies of the

patent applications.

Potentiation of Antineoplastic Agents

Using Sigma 2 Ligands

Keith W. Crawford, Wayne D. Bowen

(NIDDK)

DHHS Reference No. E–165–99/0 filed

11 May 2000

Licensing Contact: Catherine Joyce;

301/496–7735 ext. 244; e-mail:

joycec@od.nih.gov.

The inventors have developed a

therapeutic method of treating cancer

through the administration of a sigma2 receptor ligand, such as CB–184, in

combination with the anti-neoplastic

drugs, doxorubicin or actinomycin D.

The novel combination produces

marked tumor cell death at

concentrations that produce little or no

cytotoxicity when cells are exposed to

the drugs alone. The protocol may be

effective in treating tumors that are

resistant to antineoplastics alone as a

result of mutations of the p53 tumor

suppressor gene.

Tumor Markers in Ovarian Cancer

Patrice J. Morin, Colleen D. Hough,

Cheryl A. Sherman-Baust, Ellen S.

Pizer (NIA)

DHHS Reference No. E–138–00/0 filed

03 Apr 2000

Licensing Contact: Catherine Joyce;

301/496–7735 ext. 244; e-mail:

joycec@od.nih.gov.

This invention relates generally to the

identification of ovarian tumor markers

and diagnostic, prognostic and

therapeutic methods for their use. The

invention is based on the identification

of a series of ovarian tumor marker

genes that are highly expressed in

ovarian epithelial tumor cells and are

minimally expressed in normal ovarian

epithelial cells.

Imidazoacridones With Anti-Tumor

Activity

Cholody et al. (NCI)

DHHS Reference No. E–289–99/0 filed

07 March 2000

Licensing Contact: Girish Barua; 301/

496–7735 ext. 263; e-mail:

baruag@od.nih.gov.

The present invention relates to novel

bifunctional molecules with anti-tumor

activity. These agents are composed of

an imidazoacridone moiety linked by a

nitrogen containing aliphatic chain of

various length and rigidity to another

aromatic ring system capable of

intercalation to DNA.

Previous studies on related

symmetrical bis-imidazoacridones

revealed that only one planar

imidazoacridone moiety intercalates

into DNA. The second aromatic moiety

which is crucial for biological activity

resides in DNA groove, and is believed

to interact with DNA-binding proteins

(most likely, transcription factors). It

was hypothesized that action of bisimidazoacridone constitute a new

paradigm of how small molecules can

interfere with gene transcription.

To enhance the biological activity, the

inventors have developed

unsymmetrical compounds in which

one imidazoacridone system with

relatively poor DNA-intercalating

properties was replaced with much

stronger intercalators, such as 3-chloro7-methoxyacridine or naphthalimide

moieties. These new compounds,

especially those containing

naphthalimide moiety are extremely

cytotoxic against variety of tumor cells

in vitro ( IC50 at low nanomolar range)

and kill tumor cells by inducing

apoptosis. In vivo, in nude mice

xenografted with human tumors, the

compounds significantly inhibited

growth of such tumors as colon tumor

HCT116 and Colo205 as well pancreatic

tumors (lines 6.03 and 10.05 freshly

established from a patient).

Dated: February 6, 2001.

Jack Spiegel,

Director, Division of Technology Development

and Transfer, Office of Technology Transfer,

National Institutes of Health.

[FR Doc. 01–3604 Filed 2–12–01; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions;

Availability for Licensing

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice

SUMMARY: The inventions listed below

are owned by agencies of the U.S.

Government and are available for

licensing in the U.S. in accordance with

35 U.S.C. 207 to achieve expeditious

commercialization of results of

federally-funded research and

development. Foreign patent

applications are filed on selected

inventions to extend market coverage

for companies and may also be available

for licensing.

ADDRESSES: Licensing information and

copies of the U.S. patent applications

listed below may be obtained by writing

to the indicated licensing contact at the

Office of Technology Transfer, National

Institutes of Health, 6011 Executive

Boulevard, Suite 325, Rockville,

Maryland 20852–3804; telephone: 301/

496–7057; fax: 301/402–0220. A signed